To provide a compound having ability to inhibit osteoclast differentiation and induction, thus useful as an anti-inflammatory agent, antirheumatic agent or therapeutic agent for diseases associated with osteoanagenesis deficiency.
This new compound is a heterocyclic derivative of the general formula (I) [wherein, ring A and ring B are each an aromatic ring; X is NR0, S or O; R0 is H or a lower alkyl; and Y is (1) NR1R2 (wherein, R1 is a lower alkyl, lower alkenyl or lower alkynyl; R2 is an organic group other than a lower alkyl; or R1 and R2 may be bound to each other together with a nitrogen atom to form an optionally halogen-OH- or oxo-substituted saturated or unsaturated 5- to 7-membered heterocyclic ring), (2) C(=O)-NR, (3) C(OH)R or (4) an optionally substituted saturated or unsaturated 5- to 7-membered heterocyclic group] or a pharmaceutically acceptable salt thereof.
| WO/2021/195406 | NEW THERAPEUTIC USES OF COMPOUNDS |
| WO/2013/016321 | MINOR GROOVE BINDER PHOSPHORAMIDITES AND METHODS OF USE |
| JPH10204059 | PHENYLSULFONAMIDE DERIVATIVE |
HORIUCHI YOSHIHIRO
Next Patent: METHOD FOR PRODUCING 5,5-DIMETHYLOXAZOLIDINE-2,4-DIONE